International clinical psychopharmacology
-
Int Clin Psychopharmacol · Nov 2010
Psychometric evaluation of the Snaith-Hamilton pleasure scale in adult outpatients with major depressive disorder.
The inability to experience pleasure, anhedonia, is recognized as a hallmark symptom of depression. An instrument developed for the assessment of hedonic capacity is the 14-item, self-report, Snaith-Hamilton Pleasure Scale (SHAPS), but its psychometric properties have not been adequately evaluated. This study examined the reliability and validity of the SHAPS using a large sample of adult outpatients with major depressive disorder (MDD). ⋯ Pearson correlations revealed a positive linear relationship between the SHAPS total score and the total scores on the 17-item Hamilton Rating Scale for Depression (r=0.49, P<0.0001), IDS-C30 (r=0.56, P<0.0001), 16-item Quick Inventory of Depressive Symptomatology (r=0.55, P<0.0001), and 10-item clinician-rated Montgomery-Asberg Depression Rating Scale (r=0.53, P<0.0001). The SHAPS total score was negatively correlated with the Quality of Life, Enjoyment, and Satisfaction Questionnaire (r=-0.65, P<0.0001). This study shows that the SHAPS is a reliable, valid, and unidimensional instrument used to assess the hedonic capacity in adult outpatients with MDD.
-
Int Clin Psychopharmacol · Nov 2010
Comparative StudyInitial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder.
Adherence and persistence with medication therapy are important in the management of major depressive disorder. This study examined the association between initial prescription dosage of duloxetine and its adherence and persistence. In a large commercial managed-care claims database, 6132 patients with major depressive disorder were initiated on duloxetine between 1 July 2005 and 30 June 2006 at low dose (<60 mg/day, n=1989), mid dose (60 mg/day, n=3733), or high dose (>60 mg/day, n=410). ⋯ Mid-dose duloxetine-initiated patients stayed significantly longer with the medication (107.3 days) compared with low-dose (95.8 days, P<0.01) or high-dose patients (95.4 days, P<0.01). After adjustment for baseline demographics, comorbid conditions, and prior medications, mid-dose initiated patients remained to have better adherence and longer persistence than low-dose or high-dose initiators. The findings suggest that patients initiated with a dose of 60 mg/day of duloxetine seem to be more adherent to and persistent with the medication than those initiated with less or more than 60 mg/day.